Literature DB >> 27699016

Resistin-induced cardiomyocyte hypertrophy is inhibited by apelin through the inactivation of extracellular signal-regulated kinase signaling pathway in H9c2 embryonic rat cardiomyocytes.

Jian-Wei Luo1, Xian Zheng1, Guan-Chang Cheng2, Qun-Hui Ye2, Yong-Zhi Deng1, Lin Wu2.   

Abstract

It has been reported that resistin induces, whereas apelin inhibits cardiac hypertrophy. However, the underlying molecular mechanisms of apelin inhibiting resistin-induced cardiac hypertrophy remain unclear. The aim of the current study is to investigate the effects of apelin on resistin-induced cardiomyocyte hypertrophy and elucidate the underlying molecular mechanism. H9c2 cells were used in the present study, and cell surface area and protein synthesis were evaluated. Reverse transcription-quantitative polymerase chain reaction was performed to analyze the expression levels of hypertrophic markers, brain natriuretic peptide (BNP) and β-myosin heavy chain (β-MHC). In addition, western blotting was conducted to examine phosphorylation of extracellular signal-regulated kinase (ERK)1/2. Following treatment of H9c2 cells with resistin, cell surface area, protein synthesis, and BNP and β-MHC mRNA expression levels were increased. Subsequent to co-treatment of H9c2 cells with apelin and resistin, lead to the inhibition of resistin-induced hypertrophic effects by apelin. In addition, treatment with resistin increased phosphorylation of ERK1/2, whereas pretreatment with apelin decreased phosphorylation of ERK1/2, which was increased by resistin. These results indicate that resistin-induced cardiac hypertrophy is inhibited by apelin via inactivation of ERK1/2 cell signaling.

Entities:  

Keywords:  apelin; cardiac hypertrophy; extracellular signal-regulated kinase signaling pathway; resistin

Year:  2016        PMID: 27699016      PMCID: PMC5038346          DOI: 10.3892/br.2016.749

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.

Authors:  Michael W Rajala; Silvana Obici; Philipp E Scherer; Luciano Rossetti
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy.

Authors:  Peter Bobbert; Alexander Jenke; Thomas Bobbert; Uwe Kühl; Ursula Rauch; Dirk Lassner; Carmen Scheibenbogen; Wolfgang Poller; Heinz-Peter Schultheiss; Carsten Skurk
Journal:  Eur J Heart Fail       Date:  2012-07-04       Impact factor: 15.534

4.  Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats.

Authors:  Elie R Chemaly; Lahouaria Hadri; Shihong Zhang; Maengjo Kim; Erik Kohlbrenner; Jipo Sheng; Lifan Liang; Jiqiu Chen; Purushothaman K-Raman; Roger J Hajjar; Djamel Lebeche
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

5.  Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action.

Authors:  Christophe Graveleau; Vlad G Zaha; Arash Mohajer; Ronadip R Banerjee; Nicole Dudley-Rucker; Claire M Steppan; Michael W Rajala; Philipp E Scherer; Rexford S Ahima; Mitchell A Lazar; E Dale Abel
Journal:  J Biol Chem       Date:  2005-06-27       Impact factor: 5.157

6.  Role of resistin in cardiac contractility and hypertrophy.

Authors:  Maengjo Kim; Jae Kyun Oh; Susumu Sakata; Iifan Liang; Woojin Park; Roger J Hajjar; Djamel Lebeche
Journal:  J Mol Cell Cardiol       Date:  2008-05-20       Impact factor: 5.000

7.  Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility.

Authors:  István Szokodi; Pasi Tavi; Gábor Földes; Sari Voutilainen-Myllylä; Mika Ilves; Heikki Tokola; Sampsa Pikkarainen; Jarkko Piuhola; Jaana Rysä; Miklós Tóth; Heikki Ruskoaho
Journal:  Circ Res       Date:  2002-09-06       Impact factor: 17.367

Review 8.  The current biology of resistin.

Authors:  Claire M Steppan; Mitchell A Lazar
Journal:  J Intern Med       Date:  2004-04       Impact factor: 8.989

Review 9.  Extracellular signal-regulated kinases 1/2 as regulators of cardiac hypertrophy.

Authors:  Michael Mutlak; Izhak Kehat
Journal:  Front Pharmacol       Date:  2015-07-24       Impact factor: 5.810

10.  Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues.

Authors:  Wang Wang; Shaun M K McKinnie; Vaibhav B Patel; George Haddad; Zuocheng Wang; Pavel Zhabyeyev; Subhash K Das; Ratnadeep Basu; Brent McLean; Vijay Kandalam; Josef M Penninger; Zamaneh Kassiri; John C Vederas; Allan G Murray; Gavin Y Oudit
Journal:  J Am Heart Assoc       Date:  2013-07-01       Impact factor: 5.501

View more
  4 in total

Review 1.  A review of fibroblast growth factor 21 in diabetic cardiomyopathy.

Authors:  Xiang Zhang; Luo Yang; Xiongfeng Xu; Fengjuan Tang; Peng Yi; Bo Qiu; Yarong Hao
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 2.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

3.  Omentin inhibits the resistin-induced hypertrophy of H9c2 cardiomyoblasts by inhibiting the TLR4/MyD88/NF-κB signaling pathway.

Authors:  Xiaoliang Yan; Lin Wu; Min Gao; Pengjie Yang; Jinjing Yang; Yongzhi Deng
Journal:  Exp Ther Med       Date:  2022-02-17       Impact factor: 2.447

Review 4.  Overview of the Composition of Whole Grains' Phenolic Acids and Dietary Fibre and Their Effect on Chronic Non-Communicable Diseases.

Authors:  Jabir Khan; Muhammad Zahoor Khan; Yulin Ma; Yantong Meng; Aroosa Mushtaq; Qun Shen; Yong Xue
Journal:  Int J Environ Res Public Health       Date:  2022-03-05       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.